Warning letter · FDA Warning Letters, Historical Archive

Mitra Distributing Inc.: FDA Warning Letter 562402 (Sep 4, 2018)

Agency action: Sep 4, 2018Record ID: fda_warning_-e01c37cd42d4d45f
View official source ↗

What happened

Original notice title

Mitra Distributing Inc. MARCS-CMS 562402, September 04, 2018

From the archived source record

Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. 352. The marketing and sale of unapproved opioid addiction treatment products is a potentially significant threat to the public health. Unapproved New Drugs and Misbranded Drugs Claims on your website establish that the above-mentioned products are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, including opiate withdrawal and addiction, and/or because they are intended to affect the structure or function of the body. Learn more about kratom and how it can be the solution to promoting an opiate free lifestyle by visiting our About Kratom page” On the webpage with the Blog dated July 17, titled “Tragic Death of (b)(6) ”: “[I]s there a better way? In addition, your kratom products are misbranded under 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), because they lack adequate directions for use. Your above-mentioned kratom products are prescription drugs as defined in section 503(b)(1)(A) of the FD&C Act, 21 U.S.C. 353(b)(1)(A), because in light of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary to their use, they are not safe for use except under the supervision of a practitioner licensed by law to administer such drugs. A drug is misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), if the drug fails to bear adequate directions for its intended use(s). Thus, your kratom products’ labeling fail to bear adequate directions for their intended uses, which causes the products to be misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1). The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
Historical warning letter; closeout not established by annual index
Source checked
Jul 16, 2026
Record revision
4b33924db4bc

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
Bali Green Kratom Powder; Bali Red Kratom Powder; Borneo Green Kratom Powder; Borneo Red Vein Kratom; Horned Kratom Powder; Vietnam Kratom Powder; Malaysian White Vein Kratom Powder; Thai White Vein Kratom Powder; Thai Red Vein Kratom Powder; Maeng Da Kratom Powder
Company
Mitra Distributing Inc.
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.